SUBJECTS : Health Outcomes | Health Economics | Cost Of Illness Studies | Quality Of Life Studie
PharmacoEconomics - Open: 2023, vol: 7, issue: 6
- 1)- L A de Jong, X Li, S Emamipour, S van der Werf, M J Postma, P R van Dijk, T L Feenstra. Model and Empirical Data-Based Cost-Utility Studies of Continuous Glucose Monitoring in Individuals with Type 1 Diabetes: A Protocol of a Systematic Review on Methodology and Quality. PharmacoEconomics - open. 2023, 7 (6): 1007-1013
Cited : 1Read More - 2)- Marty Chaplin, Rebecca Bresnahan, Nigel Fleeman, James Mahon, Rachel Houten, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Pinki Munot. Correction: Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15. PharmacoEconomics - open. 2023, 7 (6): 1015Cited : 0Read More
- 3)- Marty Chaplin, Rebecca Bresnahan, Nigel Fleeman, James Mahon, Rachel Houten, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Pinki Munot. Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15. PharmacoEconomics - open. 2023, 7 (6): 863-875Cited : 3Read More
- 4)- Bereket Bahiru Tefera, Desalegn Getnet Demsie, Adane Yehualaw, Chernet Tafere, Kebede Feyisa, Malede Berihun Yismaw, Belayneh Kefale, Zewdu Yilma. Characteristics and Quality Appraisal of the Economic Evaluations Done in Ethiopia: A Systematic Review. PharmacoEconomics - open. 2023, 7 (6): 877-886Cited : 0Read More
- 5)- Gillian Eaglestone, Evdoxia Gkaintatzi, Harmony Jiang, Charlotte Stoner, Rosana Pacella, Paul McCrone. Cost-Effectiveness of Non-pharmacological Interventions for Mild Cognitive Impairment and Dementia: A Systematic Review of Economic Evaluations and a Review of Reviews. PharmacoEconomics - open. 2023, 7 (6): 887-914Cited : 3Read More
- 6)- Semra Ozdemir, Sean Ng, Vinh Anh Huynh, Axel Mühlbacher, Hiang Khoon Tan, Eric Andrew Finkelstein. Trade-Offs between Vaccine Effectiveness and Vaccine Safety: Personal versus Policy Decisions. PharmacoEconomics - open. 2023, 7 (6): 915-926Cited : 0Read More
- 7)- Frank Chemouni, Tiffany Chihiro Nishikawa, Harinala Groyer, Oumou Diaby, Julien Chollet, Deborah Ittah. Hospital Resource Utilization and Costs in Patients with Heart Failure in France. PharmacoEconomics - open. 2023, 7 (6): 927-940Cited : 0Read More
- 8)- Elisabeth F P Peterse, Elisabeth J M Verburg-Baltussen, Alexa Stewart, Fei Fei Liu, Christopher Parker, Maarten Treur, Bill Malcolm, Sven L Klijn. Retrospective Comparison of Survival Projections for CAR T-Cell Therapies in Large B-Cell Lymphoma. PharmacoEconomics - open. 2023, 7 (6): 941-950Cited : 1Read More
- 9)- Luis Phillipe Nagem Lopes, Alexander Itria, Luciane Cruz Lopes. Budget Impact Analysis of Risperidone Use and Adverse Event Monitoring in Autism Spectrum Disorder in Brazil: Assessment of Theoretical Versus Real Data. PharmacoEconomics - open. 2023, 7 (6): 951-961Cited : 0Read More
- 10)- Madeeha Malik, Ning Yan Gu, Azhar Hussain, Bram Roudijk, Fredrick Dermawan Purba. The EQ-5D-3L Valuation Study in Pakistan. PharmacoEconomics - open. 2023, 7 (6): 963-974Cited : 2Read More
- 11)- Ahmed Salem, Elizabeth M La, Desmond Curran, Brandon J Patterson, Justin Carrico, Stéphane Lorenc, Katherine A Hicks, Sara Poston, Christopher F Carpenter. Cost-Effectiveness of Recombinant Zoster Vaccine for the Prevention of Herpes Zoster in Hematopoietic Stem Cell Transplant Recipients and Other Immunocompromised Adults in the United States. PharmacoEconomics - open. 2023, 7 (6): 975-985Cited : 0Read More
- 12)- Claire de Oliveira, Bryan Tanner. Estimating Cumulative Health Care Costs of Childhood and Adolescence Autism Spectrum Disorder in Ontario, Canada: A Population-Based Incident Cohort Study. PharmacoEconomics - open. 2023, 7 (6): 987-995Cited : 1Read More
- 13)- Reka E Pataky, Stirling Bryan, Mohsen Sadatsafavi, Stuart Peacock, Dean A Regier. Real-World Cost Effectiveness of a Policy of KRAS Testing to Inform Cetuximab or Panitumumab for Third-Line Therapy of Metastatic Colorectal Cancer in British Columbia, Canada. PharmacoEconomics - open. 2023, 7 (6): 997-1006Cited : 1Read More
